Skip to content

Upstream Bio, Inc. UPB Q4 2024 Annual earnings

Reported March 13, 2025 · Before market open

Revenue estimate$326.3K
EPS estimate-$0.56

Next report

Aug 5, 2026 (In 3 weeks)
Revenue estimate$431.1K
EPS estimate-$0.78

Financials

Q4 2024

Income statement

See full
Revenue$613.0K+36.2%
Operating income-$26.3M-83.7%
Net income-$21.2M-79.5%

Balance sheet

See full
Cash & equivalents$325.9M+1,162%
Total debt$1.8M+3,976%
Total equity$469.9M+482%
Total assets$481.7M+311%

Cash flow

See full
Operating cash flow-$19.6M-21.7%
CapEx$185.0K+414%
Free cash flow-$19.8M-22.9%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$881.13M
Enterprise value$557.07M
P/S371.8×

Profitability

See full
Operating margin-3,281.2%
Net margin-2,650%

Returns & leverage

See full
Debt / equity
Current ratio44.6×+26.7×

Versus estimates

Ask the moment Upstream Bio, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Upstream Bio, Inc. report Q4 2024 earnings?
Upstream Bio, Inc. (UPB) reported Q4 2024 earnings on March 13, 2025 before market open.
What were Upstream Bio, Inc.'s Q4 2024 revenue and EPS?
Upstream Bio, Inc. reported revenue of $613.0K and diluted EPS of $-1.59 for Q4 2024.
Did Upstream Bio, Inc. beat estimates in Q4 2024?
Revenue beat the consensus estimate of $326.3K by $286.8K. EPS missed the consensus estimate of $-0.56 by $1.03.
Where can I find Upstream Bio, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-037621) directly on SEC EDGAR. The filing index links above go to sec.gov.